Labcorp Holdings Inc.

Equities

LH

US5049221055

Healthcare Facilities & Services

Real-time Estimate Cboe BZX 12:50:26 2024-05-22 pm EDT 5-day change 1st Jan Change
203.9 USD -0.70% Intraday chart for Labcorp Holdings Inc. -4.38% -10.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Declaration of Voting Results by Laboratory Corporation of America Holdings CI
Declaration of Voting Results by Laboratory Corporation of America Holdings CI
Declaration of Voting Results by Laboratory Corporation of America Holding CI
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing MT
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating MT
Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy CI
Tara Health Files an Exempt Solicitation Statement and Recommend Vote for its Proposal CI
Tranche Update on Laboratory Corporation of America Holdings (NYSE:LH)'s Equity Buyback Plan announced on December 9, 2021. CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $255 From $244 MT
Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy MT
US FDA publishes final rule for laboratory developed tests RE
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B CI
Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255 MT
Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234 MT
Truist Cuts Price Target on Laboratory Corp of America Holdings to $255 From $270, Keeps Buy Rating MT
Evercore ISI Cuts Laboratory Corp of America Holdings' Price Target to $210 From $225 MT
Leerink Partners Adjusts Laboratory Corp of America Price Target to $242 From $260, Keeps Outperform Rating MT
Laboratory Corp of America Q1 Adjusted Earnings, Revenue Increase; 2024 Adjusted EPS Outlook Updated MT
Transcript : Laboratory Corporation of America Holdings, Q1 2024 Earnings Call, Apr 25, 2024
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Reports Q1 Revenue $3.18B, vs. Street Est of $3.12B MT
Earnings Flash (LH) LABORATORY CORPORATION OF AMERICA HOLDINGS Reports Q1 EPS $3.68, vs. Street Est of $3.48 MT
Laboratory Corporation of America Holdings Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Labcorp beats quarterly estimates on strong testing demand RE
North American Morning Briefing : More Tech -2- DJ
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln RE
Chart Labcorp Holdings Inc.
More charts
Laboratory Corporation of America Holdings provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
205.3 USD
Average target price
239.7 USD
Spread / Average Target
+16.72%
Consensus
  1. Stock Market
  2. Equities
  3. LH Stock
  4. News Labcorp Holdings Inc.
  5. Enzo Biochem Completes Deal to Sell Clinical Laboratory Division to Laboratory Corp. of America for $113.3 Million
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW